Form 4: CFO Narayan Prabhu Granted RVPH Stock Options

Reviva Pharmaceuticals Holdings, Inc. CFO Narayan Prabhu was granted 40,925 stock options with an exercise price of $1.87, vesting over time.

Summary

• Narayan Prabhu, Chief Financial Officer of Reviva Pharmaceuticals Holdings, Inc. (RVPH), was granted 40,925 stock options.
• The options have an exercise price of $1.87 per share, based on the closing price of the common stock on the grant date.
• The grant date for these options was March 18, 2026.
• A portion of the options, 12,789 shares, vested immediately on the grant date.
• The remaining 28,136 shares will vest in equal monthly installments from April 2026 through December 2028.
• The options expire on March 17, 2036.
• This award was made under the terms of the Issuer's 2020 Equity Incentive Plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine, slightly positive event, reflecting standard executive compensation practices and management's continued alignment with shareholder interests through equity incentives.

Positives

• The grant of stock options aligns the Chief Financial Officer's financial interests with those of shareholders, incentivizing long-term company performance.
• The options provide a potential future value for the CFO, contingent on the company's stock price appreciation above the exercise price.

Negatives

• The options do not provide immediate cash compensation to the CFO.
• The value of the options is entirely dependent on the future performance of Reviva Pharmaceuticals' stock, which carries inherent market risk.

Risks

• The company's stock price could fall below the exercise price of $1.87, rendering the options worthless.
• Future market conditions or company-specific events could negatively impact the stock price, reducing or eliminating the value of the options.

Future Outlook

The filing details a standard equity incentive grant, which does not contain specific forward-looking statements or guidance regarding the company's operational or financial performance. It primarily outlines the vesting schedule for the granted options, extending through December 2028.

Management Comments

• This option award was made on March 18, 2026 (the 'Grant Date') in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the '2020 Plan').
• The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan.

Industry Context

StockSavvy.ai notes that equity grants are a common compensation tool in the biotech/pharma industry to incentivize executives and align their interests with long-term company performance, especially for companies like Reviva Pharmaceuticals that are often in development stages and rely on future value creation.

Comparison to Industry Standards

• StockSavvy.ai observes that granting stock options to key executives like the CFO is a standard practice across the biotechnology and pharmaceutical sectors, comparable to compensation structures seen at companies such as BioNTech or Moderna, where executive compensation often includes significant equity components tied to long-term performance and retention.
• The vesting schedule, with a portion vesting immediately and the remainder over several years, is typical for executive incentive plans designed to encourage retention and sustained performance.

Stakeholder Impact

• Shareholders: The grant of options aims to align the CFO's interests with long-term shareholder value creation, potentially leading to more focused management decisions.
• Employees: This reflects standard executive compensation practices, which can influence overall compensation philosophy within the company.

Next Steps

• Continued vesting of the remaining 28,136 options in equal monthly installments from April 2026 to December 2028.

Key Dates

Recommendation

The grant of stock options to the CFO is a standard compensation practice designed to align executive interests with long-term shareholder value. While not a direct indicator of immediate operational performance, it reflects ongoing executive commitment and is a neutral to slightly positive signal for a 'hold' recommendation, as it does not present new information warranting a change in investment thesis.

Keywords

Reviva Pharmaceuticals, RVPH, Stock Option, Insider Transaction, Narayan Prabhu, CFO, Equity Incentive Plan, Vesting, Form 4